Palbociclib, ribociclib, and abemaciclib belong to the third generation of cyclin-dependent kinases inhibitors (CDKis), an established therapeutic class for advanced and metastatic breast cancer. Interindividual variability in the therapeutic response of CDKis has been reported and some individuals may experience increased and unexpected toxicity. This narrative review aims at identifying the factors potentially concurring at this variability for driving the most appropriate and tailored use of CDKis in the clinic. Specifically, concomitant medications, pharmacogenetic profile, and pathophysiological conditions could influence absorption, distribution, metabolism, and elimination pharmacokinetics. A personalized therapeutic approach taking into consideration all factors potentially contributing to an altered pharmacokinetic/pharmacodynamic profile could better drive safe and effective clinical use.
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions / R. Roncato, J. Angelini, A. Pani, E. Cecchin, A. Sartore-Bianchi, S. Siena, E. De Mattia, F. Scaglione, G. Toffoli. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 21:17(2020 Sep 01), pp. 6350.1-6350.32.
|Titolo:||CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions|
|Parole Chiave:||breast cancer; cyclin-dependent kinases inhibitors; personalized medicine|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||1-set-2020|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.3390/ijms21176350|
|Appare nelle tipologie:||01 - Articolo su periodico|